Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Coping with hair loss, the effects of finasteride and minoxidil, and strategies for maintaining self-esteem while experiencing hair loss.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

Pyrilutamide from Ligand Chem was used by several individuals to address hair loss, with mixed results and no significant side effects reported. Some users switched to Minoxidil Max for better value, while others noted no hair growth or only a reduction in shedding.

Breezula protects hair follicles from both testosterone and DHT, unlike finasteride, which only protects against DHT. This could potentially lead to significant hair regrowth, similar to results seen in transgender individuals using hormone blockers.

The user has been using topical minoxidil and dutasteride but is experiencing significant hair shedding, including smaller hairs. They are concerned if this shedding indicates the treatment is working.

The user started oral finasteride and minoxidil in November 2024, initially saw improvement, but has experienced increased shedding since April 2025. They are concerned the treatment may not be effective anymore and seek advice.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation is about hair regrowth progress using topical finasteride and minoxidil twice daily, with occasional microneedling. The user also uses Minoxidilmax and WOW Skin Science Apple Cider Vinegar Shampoo.

LLLT (low-level laser therapy) is as effective or better than traditional minoxidil treatment for hair growth, with fewer side effects and improved long-term compliance due to milder adverse effects. Studies show LLLT increases hair density more than minoxidil, but drawbacks include the initial cost and the need for long-term use to see results.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.

Comparing scalp hair to facial hair, and the effects of DHT on growth. Possible treatments discussed include Minoxidil, finasteride and RU58841.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

The user is concerned about whether their hair styling is causing thinning or if it's natural. They are considering treatments like Minoxidil, finasteride, or RU58841 for hair loss.

The conversation discusses the effectiveness of an eyebrow serum containing Myristoyl Pentapeptide and Biotinoyl Tripeptide for hair growth. The user seeks information on other topical products with similar peptides for hair growth.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

Hair loss progress discussed with 4.5 months on topical fin (0.025% liposomal). User uses rosemary oil for scalp health, and others think there might be some thickening or maintenance.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

Switching from liquid to foam minoxidil may cause mild shedding, possibly due to differences in absorption. Returning to the original liquid formulation typically stabilizes shedding within a few weeks.

The trichologist avoids recommending Minoxidil, focusing instead on changing medications monthly for seborrheic dermatitis, resulting in only slight improvement in hair quality and loss. The user is considering starting Minoxidil independently due to slow progress and personal distress.

User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.

A 30-year-old woman with a history of anemia and low vitamin D experienced hair shedding, which improved after addressing nutrient deficiencies. Despite regrowth of terminal hairs, her dermatologist recommended treatments like minoxidil and spironolactone to prevent future bald spots, but she is cautious due to family history of hormone-related cancers.

The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user followed a hair loss treatment routine using liquid minoxidil, oral minoxidil, and oral finasteride, with plans to stop topical minoxidil by mid-2026. They experienced significant improvement, especially in the crown area, after starting oral minoxidil.

Minoxidil is highly toxic to pets, particularly cats and dogs, and there is a call for proper labeling to warn pet owners. Despite some skepticism about the effectiveness of petitions, many agree that awareness and caution are necessary to prevent accidental poisoning.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The user is experiencing significant hair shedding despite 2 years on finasteride, 1.5 years on RU58841, and 10 months on oral minoxidil, and is frustrated with the ongoing issue. Another user shares a similar experience of losing a lot of hair daily for the last 3 years.